LGT Fund Management Co Ltd. Makes New $1.07 Million Investment in Becton, Dickinson and Company $BDX

LGT Fund Management Co Ltd. purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, Holdings Channel reports. The institutional investor purchased 6,808 shares of the medical instruments supplier’s stock, valued at approximately $1,070,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $25,000. Steph & Co. lifted its holdings in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares in the last quarter. SHP Wealth Management purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in Becton, Dickinson and Company during the fourth quarter valued at $29,000. Finally, WPG Advisers LLC boosted its position in shares of Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 61 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 5,188 shares of company stock worth $765,120. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.1%

NYSE:BDX opened at $152.16 on Monday. The firm has a 50-day simple moving average of $148.25 and a two-hundred day simple moving average of $167.60. The firm has a market cap of $41.93 billion, a P/E ratio of 38.52, a P/E/G ratio of 10.75 and a beta of 0.21. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter in the prior year, the company posted $3.35 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were paid a $1.05 dividend. The ex-dividend date was Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. Becton, Dickinson and Company’s payout ratio is currently 106.33%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on BDX shares. TD Cowen dropped their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Argus dropped their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Barclays boosted their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, The Goldman Sachs Group reduced their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $180.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.